肽基精氨酸脱亚氨酶Ⅳ(PADI4)活性蛋白
Active Peptidyl Arginine Deiminase Type IV (PADI4)
PAD; PADI5; PDI4; PDI5; Peptidyl Arginine Deiminase Type V; Peptidylarginine deiminase IV
- 编号APF709Hu01
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 缓冲液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性状冻干粉
- 纯度> 95%
- 等电点6.0
- 应用Cell culture; Activity Assays.
- 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 暂无报价 暂无报价 暂无报价 暂无报价 暂无报价
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
Figure. SDS-PAGE
-
通过ISO 9001、ISO 13485质量体系认证
活性实验
Peptidylarginine deiminase 4 (PADI4) is an enzyme that plays an important role in the organism. It mainly catalyzes the conversion of arginine residues in proteins into citrulline residues. PADI4 plays a key role in various physiological processes such as cell differentiation and immune response. The abnormal expression or change in its activity is closely related to autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, making it an important target in the research of these related diseases.The activity of recombinant human PADI4 is determined by its ability to catalyze Benzoyl-arginine ethyl ester (BAEE) to form citrulline.The reaction was performed in 50 mM Tris, 0.1 M NaCl, 10 mM CaCl2, 5 mM DTT solution (Assay Buffer, pH 7.5). A total volume of 300 μL was achieved by adding 75 μL of 100 μg/mL PADI4 to 75 μL of 10 mM BAEE. After 30-minute incubation at 37°C, the reaction mixture was acidified with color-developing solution containing ammonium iron sulfate and measured at 540 nm .
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月，-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| APF709Hu01 | 肽基精氨酸脱亚氨酶Ⅳ(PADI4)活性蛋白 | Cell culture; Activity Assays. |
| RPF709Hu01 | 肽基精氨酸脱亚氨酶Ⅳ(PADI4)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAF709Hu01 | 肽基精氨酸脱亚氨酶Ⅳ(PADI4)多克隆抗体 | WB; IHC; ICC; IP. |
| MAF709Hu21 | 肽基精氨酸脱亚氨酶Ⅳ(PADI4)单克隆抗体 | WB |
| MAF709Hu22 | 肽基精氨酸脱亚氨酶Ⅳ(PADI4)单克隆抗体 | WB; IHC; ICC; IP. |
| MAF709Hu23 | 肽基精氨酸脱亚氨酶Ⅳ(PADI4)单克隆抗体 | WB; IHC; ICC; IP. |
| MAF709Hu24 | 肽基精氨酸脱亚氨酶Ⅳ(PADI4)单克隆抗体 | WB; IHC; ICC; IP. |
| FAF709Hu02 | 抗肽基精氨酸脱亚氨酶Ⅳ(PADI4)单克隆抗体 | FCM |
| SEF709Hu | 肽基精氨酸脱亚氨酶Ⅳ(PADI4)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMF709Hu | 肽基精氨酸脱亚氨酶Ⅳ(PADI4)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| Arthritis Res Ther. | Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility [Pubmed:Pmc4229860] |
| Journal of Molecular Cell Biology | Peptidylarginine deiminase 4 concentration, but not polymorphisms, is associated with ICU mortality in septic shock patients [Pubmed:30044533] |
| Journal of Inflammation Research | Release of active peptidylarginine deiminase into the circulation during acute inflammation induced by coronary artery bypass surgery [Pubmed: 31213874] |
| Revista da Associacao Medica Brasileira | Evaluation of peptidylarginine deiminase 4 and PADI4 polymorphisms in sepsis-induced acute kidney injury [] |
